Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2014

View Archived Issues

New mouse model of ulcerative colitis developed to investigate the ileal epithelial barrier

TNI BioTech forms new subsidiary, Cytocom

Amarantus acquires option to license intellectual property for MANF and CDNF

Takeda files for Japanese approval of trelagliptin succinate for type 2 diabetes

Valneva signs cell-line agreement with Emergent BioSolutions for vaccine development

Tamoxifen found to have potential in treating spinal cord injury

Arena Pharmaceuticals reports discovery of H3 receptor antagonists

Galapagos earns partial milestone payment under osteoarthritis alliance with Servier

Cancer Therapeutics CRC discloses new VEGFR-3 inhibitors for cancer

Yissum Research Development synthesizes cytotoxic vanadium and titanium complexes

AiCuris patents new RT inhibitors for HIV infection

Bayer patent divulges novel BRD4 inhibitors

Bayer Group completes takeover offer for Algeta

Interim phase III data show BPL factor X is well tolerated in patients with hereditary FX deficiency

Sirturo obtains conditional approval in the E.U. for multidrug-resistant tuberculosis

Digital Aria signs agreement to develop RegeneRx's RGN-259 and RGN-137

Independent committee recommends continuation of phase III trial of algenpantucel-L

MolMed requests conditional marketing authorization for TK therapy in the E.U.

Fibrotech completes phase Ia study of FT-011 for diabetic nephropathy

Torii reports results from domestic study of TO-203 for house dust mite-induced allergic rhinitis

Transition from pdFIX to newly developed rFIX, BAX-326, is safe and clinically effective

New grant supports ThromboGenics' research in DME

C3 Jian begins phase II study of C-16G2 for prevention of dental caries

Researchers develop a novel 7-microRNA hematologic cancer panel

Phase IIb/III trial of EPI-743 begins in Leigh syndrome

Cytox initiates clinical trials of mTOR blood tests for dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...